Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno™ and Modusik-A Ofteno™


Por: Quintana-Hau J.D., Cruz-Olmos E., López-Sánchez M.I., Sánchez-Castellanos V., Baiza-Durán L., González J.R., Tornero-Montaño R., Mondragón-Flores R., Hernández-Santoyo A.

Publicada: 1 ene 2005
Resumen:
Sophisen, a new ophthalmic drug carrier, was characterized using physicochemical and morphological criteria. Diclofenac belongs to a nonsteroidal anti-inflammatory molecule group and its ophthalmic use avoids side effects produced by steroid drugs. Cyclosporine-A is a cyclic peptide used as an immunosuppressive when administrated systemically. Its application in ophthalmology has been reported, but it is a very poor soluble drug. Diclofenac sodium and Cyclosporine-A were mixed with Sophisen to render two new ophthalmic solutions that were named 3A Ofteno™ and Modusik-A Ofteno™, respectively. Based on transmission electron microscopy and dynamic light scattering studies, we concluded that Sophisen is a polydisperse solution with a molecular weight of 413±122 kDa, whereas 3A Ofteno™ and Modusik-A Ofteno™ are monodisperse solutions with molecular weights of 169±44 and 153±10, respectively. Sophisen was shown to be a good carrier for diclofenac sodium as evaluated by passive diffusion through the cornea. A comparative study suggests that diclofenac applied as eye drops was better tolerated when associated with Sophisen. In addition, Modusik-A Ofteno™, a new aqueous solution of Cyclosporine-A, improved tear production in patients with moderate or severe dry eye condition. Copyright ©2005 Taylor & Francis Inc.

Filiaciones:
Quintana-Hau J.D.:
 Research and Development Department, Laboratories Sophia, Guadalajara, Jalisco, Mexico

 Research and Development Department, Laboratorios Sophia, 797 Hidalgo, Guadalajara, Jalisco 44290, Mexico

Cruz-Olmos E.:
 Research and Development Department, Laboratories Sophia, Guadalajara, Jalisco, Mexico

López-Sánchez M.I.:
 Research and Development Department, Laboratories Sophia, Guadalajara, Jalisco, Mexico

Sánchez-Castellanos V.:
 Research and Development Department, Laboratories Sophia, Guadalajara, Jalisco, Mexico

Baiza-Durán L.:
 Research and Development Department, Laboratories Sophia, Guadalajara, Jalisco, Mexico

González J.R.:
 Research and Development Department, Laboratories Sophia, Guadalajara, Jalisco, Mexico

Tornero-Montaño R.:
 Research and Development Department, Laboratories Sophia, Guadalajara, Jalisco, Mexico

Mondragón-Flores R.:
 Departamento de Bioquímica, Ctro. de Invest. Y Estud. Avanzados, México D.F., Mexico

Hernández-Santoyo A.:
 Instituto de Química, Univ. Nac. Auton. de Mex., Ciudad Universitaria, México D.F., Mexico
ISSN: 03639045
Editorial
TAYLOR & FRANCIS LTD, 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND, Estados Unidos America
Tipo de documento: Article
Volumen: 31 Número: 3
Páginas: 263-269
ID de PubMed: 15830722